Pfizer Inc.
NYSE:PFE 11:14:58 AM EDT
Products, Other Pre-Announcement
Pfizer Says 2023 Paxlovid Guidance Assumes No Sales After April 1 To China
Published: 01/31/2023 12:35 GMT
Pfizer Inc. (PFE) - Pfizer Inc - 2023 Paxlovid Guidance Assumes No Sales After April 1, 2023 to China.
Pfizer Sees Estimated Timing for Transitioning Comirnaty and Paxlovid to Commercial Market in the U.S. in Second Half of 2023.
Pfizer Expects About 24% of the U.S. Population – Or 79 Million People – to Receive Covid-19 Vaccine Doses During 2023.
Pfizer Says Expects U.S. Covid Vaccination Rates to Be Flat in 2024 Versus 2023.
Pfizer Sees U.S. Covid-19 Vaccination Rates to Increase in 2025 and 2026 If a Combination Covid/flu Vaccine is Approved.
Pfizer Says Expects Will Be Able to Sell Paxlovid in China "effectively Under Government Reimbursement Through March".
Pfizer Sees Estimated Timing for Transitioning Comirnaty and Paxlovid to Commercial Market in the U.S. in Second Half of 2023.
Pfizer Expects About 24% of the U.S. Population – Or 79 Million People – to Receive Covid-19 Vaccine Doses During 2023.
Pfizer Says Expects U.S. Covid Vaccination Rates to Be Flat in 2024 Versus 2023.
Pfizer Sees U.S. Covid-19 Vaccination Rates to Increase in 2025 and 2026 If a Combination Covid/flu Vaccine is Approved.
Pfizer Says Expects Will Be Able to Sell Paxlovid in China "effectively Under Government Reimbursement Through March".